New drug TS-172 tested in patients with liver impairment
NCT ID NCT07231029
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing how the drug TS-172 behaves in the bodies of people with mild or moderate liver impairment. Researchers will measure drug levels in the blood to see if liver function affects how the drug is processed. The study involves 24 Japanese adults and is currently recruiting participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TS-172
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taisho Pharmaceutical Co., Ltd selected site
RECRUITINGTokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver health and drug processing: a closer look at casdatifan
- Liver function may change how belapectin works in the body
- Liver function may change how ammoxetine works
- Liver function may affect how Weight-Loss drug petrelintide works
- Liver health may change how a promising cancer drug works in the body
- Liver health may change how body handles inhaled lung drug